These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37705206)

  • 1. Global VALIANT study: 'lifting the lid' on disappointment and frustration with the lack of effective treatment for vitiligo.
    Ahmed A; Eleftheriadou V
    Br J Dermatol; 2023 Nov; 189(6):e99-e102. PubMed ID: 37705206
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study.
    Hamzavi IH; Bibeau K; Grimes P; Harris JE; van Geel N; Parsad D; Tulpule M; Gardner J; Valle Y; Tlhong Matewa G; LaFiura C; Ren H; Ezzedine K
    Br J Dermatol; 2023 Oct; 189(5):569-577. PubMed ID: 37493275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation and study of stem cell transplantation in treatment of vitiligo.
    Liu J; Liu S; Guo M; Yong M; Hu Z
    Arch Dermatol Res; 2023 Dec; 315(10):2983-2984. PubMed ID: 37676313
    [No Abstract]   [Full Text] [Related]  

  • 4. What is successful repigmentation in vitiligo from the point of view of patients?
    Narayan VS; Uitentuis SE; Bekkenk MW; Wolkerstorfer A
    Br J Dermatol; 2021 Jan; 184(1):165-166. PubMed ID: 32726875
    [No Abstract]   [Full Text] [Related]  

  • 5. Current Status of Cell-Based Therapies for Vitiligo.
    Domaszewska-Szostek A; Polak A; Słupecka-Ziemilska M; Krzyżanowska M; Puzianowska-Kuźnicka M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does low-intensity pulsed ultrasound enhance repigmentation in vitiligo?
    Sindhuja T; Chandra AD; Pathak M; Gupta V
    Dermatol Ther; 2022 Jul; 35(7):e15523. PubMed ID: 35439348
    [No Abstract]   [Full Text] [Related]  

  • 7. Global recommendations for vitiligo management.
    Ring J
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2157-2158. PubMed ID: 37877761
    [No Abstract]   [Full Text] [Related]  

  • 8. Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide.
    Br J Dermatol; 2023 Oct; 189(5):e94. PubMed ID: 37879743
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser.
    Murakami K; Saito Y; Takeuchi S; Sujino K; Tanikawa A; Tanese K; Fukuda K
    Eur J Dermatol; 2023 Aug; 33(4):428-430. PubMed ID: 37823495
    [No Abstract]   [Full Text] [Related]  

  • 10. Eight-year sustained efficacy and safety of fractional CO
    Helou J; Soutou B
    J Cosmet Dermatol; 2022 Nov; 21(11):6518-6520. PubMed ID: 35980675
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of 308-nm excimer laser treatment for refractory vitiligo: a case series of treatment based on the minimal blistering dose.
    Noborio R; Nomura Y; Nakamura M; Nishida E; Kiyohara T; Tanizaki H; Morita A
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):e287-e289. PubMed ID: 33232541
    [No Abstract]   [Full Text] [Related]  

  • 12. Repigmentation of acral vitiligo with tofacitinib combined with NB-UVB phototherapy: A case report.
    Sun XK; Xu AE
    Australas J Dermatol; 2023 Nov; 64(4):571-572. PubMed ID: 37635652
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of noncultured melanocyte-keratinocyte cell suspension vs hair follicular cell suspension transfer in stable vitiligo: A randomized controlled trial.
    Moosavi Z; Miramin Mohammadi A; Tavakkoli K; Daniel VT; Variji Z; Javadi A; Feizi Konjini L; Firooz A
    Dermatol Ther; 2020 May; 33(3):e13309. PubMed ID: 32162392
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of diversity in vitiligo clinical trials: a cross-sectional analysis.
    Hernandez LE; Verling S; Nouri K
    Arch Dermatol Res; 2023 Nov; 315(9):2735-2736. PubMed ID: 37486414
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing the trends of outcome measures and quality of life instruments in vitiligo: A systematic review.
    Maghfour J; Shoukfeh R; Hamzavi IH; Ezzedine K; Mohammad TF
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2270-2272. PubMed ID: 37566732
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of micro-needling combined with topical 5-fluorouracil and excimer light vs. excimer light alone in treatment of non-segmental vitiligo: A comparative study.
    Saad MA; Tawfik KM; Abdelaleem HL
    J Cosmet Dermatol; 2023 Mar; 22(3):810-821. PubMed ID: 36343160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do health insurers have an ethical responsibility to cover treatment of vitiligo?
    Bercovitch L
    Pediatr Dermatol; 2021 Nov; 38 Suppl 2():187. PubMed ID: 34850431
    [No Abstract]   [Full Text] [Related]  

  • 18. Repigmentation of poliosis in a patient with segmental vitiligo.
    Bae JM; Kwon HS; Lee JH; Kim GM
    J Am Acad Dermatol; 2016 Jul; 75(1):e23-4. PubMed ID: 27317537
    [No Abstract]   [Full Text] [Related]  

  • 19. Ultra-violet therapy in cases of leucoderma.
    MENON AN
    Ind Med Gaz; 1945 Dec; 80(12):612-4. PubMed ID: 21026566
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding the impacts of vitiligo to provide better care.
    Meurant JM
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2161-2162. PubMed ID: 37877765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.